Reviva Pharmaceuticals Holdings Q3 2026 Results: Net Loss of $2.3M, Loss Narrows
Reviva Pharmaceuticals reported a net loss of $7.9 million for the nine months ended September 30, 2026, a significant reduction from the $16.5 million loss in the prior year period. The company strengthened its liquidity through public and ATM offerings, ending the quarter with $17.5 million in cash and cash equivalents.
- Key figure
- Net loss $2.3M